Skip to main content
Oxford Research Peptides
MECHANISM NOTE

Glucagon Receptor Explained

A concise reference on the glucagon receptor — its classification, signalling and its role as the third receptor engaged by triple-agonist research peptides.

QUICK ANSWER
TL;DR

Quick answer

The glucagon receptor (GCGR) is a class B G-protein-coupled receptor activated by the pancreatic peptide hormone glucagon. It is highly expressed in liver hepatocytes, couples to Gαs and Gαq, and is the third receptor engaged by triple-agonist research peptides such as Retatrutide.
EXTENDED ANSWER
AI-ready

Extended answer

What is the glucagon receptor and why is it engaged by triple-agonist peptides?

The glucagon receptor (GCGR) is a class B secretin-like G-protein-coupled receptor activated by the 29-residue pancreatic peptide hormone glucagon, which is secreted from pancreatic α-cells principally in response to hypoglycaemia. GCGR couples primarily to Gαs and elevates intracellular cyclic AMP, with additional Gαq coupling that supports calcium mobilisation. It is highly expressed in hepatocytes, where activation drives gluconeogenesis and glycogenolysis; reported effects also extend to hepatic lipid handling and thermogenesis. Adding controlled GCGR activity to a GLP-1R / GIPR scaffold is the defining feature of the triple-agonist category exemplified by Retatrutide, and the scientific rationale centres on possible metabolic effects that a pure incretin agonist may not achieve. In-vitro pharmacology at GCGR is characterised by cAMP-response assays and, orthogonally, calcium-mobilisation readouts in recombinant systems.
KEY FACTS

Key facts

Receptor class
Class B GPCR (secretin-like)
Endogenous ligand
Glucagon (1-29)
Primary coupling
Gαs / cAMP (also Gαq)
Primary tissue
Hepatocytes

Classification

GCGR is a class B (secretin-like) seven-transmembrane G-protein-coupled receptor, structurally related to GLP-1R and GIPR and part of the same receptor superfamily.[6]

Endogenous ligand and signalling

The endogenous ligand at GCGR is the 29-residue pancreatic peptide hormone glucagon, secreted by pancreatic α-cells principally in response to hypoglycaemia. GCGR couples primarily to Gαs, elevates intracellular cyclic AMP and, in hepatocytes, activates gluconeogenesis and glycogenolysis. Additional Gαq coupling contributes to intracellular calcium mobilisation.

Physiological role

  • Hepatic glucose output: Glucagon drives glycogen breakdown and gluconeogenesis in the liver.
  • Lipid handling: Reported effects on hepatic lipid oxidation and triglyceride export.
  • Energy expenditure: Preclinical models associate glucagon signalling with modulation of thermogenesis.

Why GCGR appears in triple-agonist scaffolds

Retatrutide's distinguishing pharmacological feature is the controlled addition of glucagon-receptor activity to a GLP-1R / GIPR scaffold, producing a balanced triple agonist at the three related class B GPCRs.[1] The scientific rationale for combining GCGR activity with incretin-receptor agonism is the potential for effects on hepatic lipid handling and energy expenditure that a pure incretin agonist may not achieve.

Working with GCGR in vitro

Recombinant human GCGR expressed in HEK293 or CHO cell lines supports cAMP-based functional assays. Because GCGR displays non-trivial Gαq coupling, calcium-mobilisation readouts are also reported in the literature and can be a useful orthogonal assay.

Where to go next

References6

  1. 1.

    Coskun T, Urva S, Roell WC, et al.. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.. Cell Metabolism. 2022;34(9):1234-1247.

    DOI: 10.1016/j.cmet.2022.07.013PMID: 35985340
  2. 2.

    Jastreboff AM, Kaplan LM, Frías JP, et al.. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial.. New England Journal of Medicine. 2023;389(6):514-526.

    DOI: 10.1056/NEJMoa2301972PMID: 37366315
  3. 3.

    Rosenstock J, Frias J, Jastreboff AM, et al.. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial.. The Lancet. 2023;402(10401):529-544.

    DOI: 10.1016/S0140-6736(23)01053-XPMID: 37385275
  4. 4.

    Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP.. Gastroenterology. 2007;132(6):2131-2157.

    DOI: 10.1053/j.gastro.2007.03.054PMID: 17498508
  5. 5.

    Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1.. Cell Metabolism. 2018;27(4):740-756.

    DOI: 10.1016/j.cmet.2018.03.001PMID: 29617641
  6. 6.

    de Graaf C, Donnelly D, Wootten D, et al.. Glucagon-like peptide-1 and its class B G protein–coupled receptors: a long march to therapeutic successes.. Pharmacological Reviews. 2016;68(4):954-1013.

    DOI: 10.1124/pr.115.011395PMID: 27736833
EVIDENCE SUMMARY
Evidence

Evidence summary

Strong evidence
Research confidenceHigh confidence
GCGR is a well-characterised receptor with decades of independent literature. Its role within triple-agonist scaffolds is more recent and continues to develop.
RELATED GUIDES
COMPOUNDS TARGETING GCGR
EDITORIAL NOTICE

Research use only

All materials referenced are supplied strictly for in-vitro laboratory research. Not for human or animal consumption, diagnosis, or therapeutic use.
VERSION HISTORY
Editorial Team
Oxford Research Peptides Editorial Team
In-house editorial staff
Oxford Research Peptides
Scientific Reviewer
Scientific Review Panel
Independent scientific review
Oxford Research Peptides

Publication information

Published
2026-07-15
Updated
2026-07-15
Reviewed
2026-07-15
Version
1.0

Revision history

  1. v1.02026-07-15· Editorial Team

    Initial publication as part of the Retatrutide authority cluster (Release 4.0).

Editorial standards

Content is reviewed against our editorial process for scientific accuracy, sourcing, and clarity. Read our editorial standards.

Conflict of interest

Oxford Research Peptides supplies research-grade reference peptides commercially. Editorial pages are drafted and reviewed to describe published scientific literature accurately and do not recommend, promote or endorse any specific commercial product. Product mentions on educational pages are strictly for cross-referencing catalogue entries.

Next scheduled review: 2028-01-15. Our research methodology describes how the review is conducted.

Research use only

All materials referenced are supplied strictly for in-vitro laboratory research. Not for human or animal consumption, diagnosis, or therapeutic use.
Published: 2026-07-15Updated: 2026-07-15